Risankizumab
Chemical compound
Risankizumab ( RIS-ən-KIZ-uu-mab), sold under the brand name Skyrizi ( sky-RIZZ-ee), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.
Nº Q25112466 ★★
Uncommon · Knowledge
Risankizumab
Chemical compound
Risankizumab ( RIS-ən-KIZ-uu-mab), sold under the brand name Skyrizi ( sky-RIZZ-ee), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.
Last price
—
Floor price
—
7-day median
—
30-day sales
0
30-day range
—
In circulation
0
Price history
median
low – high
sales
No sales in this period
Show table
| Date | median | Low | High | sales |
|---|
Sales history
- Last sale
- —
- 30-day average
- —
- 30-day low
- —
- 30-day high
- —
- Sales 7d
- 0
- Sales 30d
- 0
No sales yet.
Anonymous sales: no buyer or seller shown. Figures count player-to-player sales only.
From Wikipedia
Risankizumab ( RIS-ən-KIZ-uu-mab), sold under the brand name Skyrizi ( sky-RIZZ-ee), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection. The most common side effects include upper respiratory infections (nose and throat infection). Risankizumab is approved for medical use in the European Union, the United States, Canada, and Japan.
Text: Wikipédia, CC BY-SA 4.0. · Image: British Columbia Institute of Technology (BCIT). Download th... (CC BY 4.0) ·
